[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Even If Eli Lilly Stock Continues to Shine, Stay Away from This Pharmaceutical ETF

One of the biggest misconceptions about ETFs is that they are highly diversified “baskets” of stocks. Sometimes they are. But as the iShares US Pharmaceuticals ETF (IHE) indicates, even with 60 stock holdings and $1 billion in assets, large ETFs can still be more of a duopoly than a democracy. 

With 44% allocated to just two stocks, and 60% allocated across the top six names, the rest are essentially along for the ride. With that important note established, let’s look at the potential up-move IHE is hinting at. 

Fundamentals

See More
  • Market Capitalization, $K 538,037,056
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.26
  • Price/Sales 5.76
  • Price/Cash Flow 15.96
  • Price/Book 6.68

Options Overview Details

View History
  • Implied Volatility 24.65% (+0.89%)
  • Historical Volatility 19.06%
  • IV Percentile 88%
  • IV Rank 70.01%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 2) 3.88 (1.74%)
  • Put/Call Vol Ratio 0.43
  • Today's Volume 17,297
  • Volume Avg (30-Day) 22,159
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 346,935
  • Open Int (30-Day) 346,463
  • Expected Range 219.01 to 226.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 7
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.37 +1.14%
on 05/11/26
235.49 -5.35%
on 05/22/26
-4.30 (-1.89%)
since 05/01/26
3-Month
220.37 +1.14%
on 05/11/26
247.88 -10.08%
on 03/03/26
-25.67 (-10.33%)
since 03/02/26
52-Week
149.04 +49.55%
on 06/20/25
251.71 -11.45%
on 03/02/26
+67.49 (+43.43%)
since 06/02/25

Most Recent Stories

More News
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

LONDON , June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index...

JNJ : 222.89 (-0.28%)
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

LONDON , June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe...

JNJ : 222.89 (-0.28%)
Even If Eli Lilly Stock Continues to Shine, Stay Away from This Pharmaceutical ETF

The rest of the stocks in the IHE ETF make it an unappealing way to play the pharma industry here.

IHE : 88.99 (-1.44%)
JNJ : 222.89 (-0.28%)
LLY : 1,064.15 (-1.67%)
PPH : 101.22 (-1.04%)
$DOWI : 51,307.79 (+0.45%)
3 Dividend Kings That Earn Their Crown Every Quarter

These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential

JNJ : 222.89 (-0.28%)
BDX : 144.43 (-0.62%)
KVUE : 17.32 (-0.17%)
PEP : 142.00 (+0.34%)
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

CHICAGO , May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj...

JNJ : 222.89 (-0.28%)
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

CHICAGO , May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus...

JNJ : 222.89 (-0.28%)
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

CHICAGO , May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT ® (amivantamab-vmjw)...

JNJ : 222.89 (-0.28%)
Unusual Options Activity Points to Boston Scientific Stock as a Hot M&A Target

Boston Scientific posted two of the top three Volume-to-Open Interest ratios during Thursday's trading session, a notable signal often associated with heightened market speculation. This unusual options...

BSX : 47.68 (-0.63%)
JNJ : 222.89 (-0.28%)
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

XLV : 146.40 (-0.97%)
JNJ : 222.89 (-0.28%)
ABBV : 215.40 (+1.16%)
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

CHICAGO , May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically...

JNJ : 222.89 (-0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 229.53
2nd Resistance Point 227.52
1st Resistance Point 225.20
Last Price 222.89
1st Support Level 220.87
2nd Support Level 218.86
3rd Support Level 216.54

See More

52-Week High 251.71
Last Price 222.89
Fibonacci 61.8% 212.49
Fibonacci 50% 200.38
Fibonacci 38.2% 188.26
52-Week Low 149.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.